HQ Location:
Lexington, MA
Date invested:
2017
Status:
IPO - February 28th, 2019
NASDAQ: KLDO
website:
Kaleido Biosciences is a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome to treat disease and improve human health.
What if we were to view the microbiome not as a vast collection of different microbe species, but as a single organ with critical functions? It turns out we can create and administer drugs targeting the microbiome as a whole, and potentially drive beneficial effects across a range of disease states and conditions (including diabetes, cardiovascular, liver, kidney, and infectious diseases).
People:
